Latest Headlines

  1. Sartorius Stedim Biotech Supports Mainstream Adoption Of Quality By Design

    Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing. It will allow customers to adopt a Quality by Design (QbD) approach in which they build quality into their biological products by combining the power of highthroughput mini bioreactors with data analysis and knowledge management tools so that robust and well-characterized processes can be scaled up at the first attempt.

  2. The German National Center For Tumor Diseases (NCT) Heidelberg And Protagen AG Investigate Responsiveness To Checkpoint Inhibitors In Melanoma

    The German National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG recently announced a collaboration to utilize Protagen’s SeroTag technology to identify biomarkers that predict therapy responsiveness and the detection of immune-related adverse events (irAEs) in melanoma patients treated with checkpoint inhibitors

  3. Sartorius Stedim Biotech Opens New Validation Service Lab At Shanghai Site

    Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new validation service laboratory yesterday at its site in Shanghai Zhangjiang Hi-Tech Park. The opening event was attended by business partners from the biopharmaceutical industry and representatives of the local community.

  4. CPhI Worldwide Experts Make Pharma Predictions For 2017: The Good, The Bad, And The Donald

    The CPhI Worldwide expert panel predicts pharma’s biggest opportunities and threats in 2017 – the wider industry, attendees and exhibitors increasingly look to the CPhI global events as a key indicator of future trends and partnerships.

  5. Malin Announces Investment In Cilatus BioPharma AG

    Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based and globally operating life sciences company, today announced that it has acquired an 80% shareholding of Cilatus BioPharma AG 

  6. Clovis Oncology Announces Proposed Offering Of Common Stock

    Clovis Oncology, Inc. announced recently that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175M.

  7. Adding Multimedia And Conference Call Details Clovis Oncology Announces FDA Accelerated Approval Of Rubraca (Rucaparib) For The Monotherapy Treatment Of Advanced Ovarian Cancer In Women With Deleterious Germline Or Somatic BRCA Mutations

    Clovis Oncology, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.

  8. MilliporeSigma Announces Winner Of Life Science Award In Bioseparations

    MilliporeSigma recently announced that Ying Li, from The Pennsylvania State University, has won the company’s Life Science Award in Bioseparations.

  9. Life Science Connect Appoints Chief Editor And Business Development Positions

    Life Science Connect, a business unit within the pioneering B2B media services company VertMarkets, announced two new appointments to the company’s Life Sciences team. Bob Marshall joins the Life Science Connect team as the Editor In Chief of Med Device Online.

  10. Sartorius Stedim Announces Expansion Of Sartorius Stedim Cellca

    Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track.